---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-266688"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2026-06-11T11:12:53+00:00"
generated_at: "2026-06-11T11:15:17.200594+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Climb Bio Announces Positive Initial Phase 1b Data for Budoprutug in Immune Thrombocytopenia

## Summary
- Phase 1b enrolled 15 patients at 250 mg (n=6) and 500 mg (n=9) doses, median follow-up 38 and 12 weeks respectively.
- Budoprutug was well tolerated with no serious adverse events, no discontinuations, and all AEs Grade 1-2.
- In 250 mg cohort, B-cells depleted by >90% at Week 4; mean platelet count increased by 111,000/µL at Week 24.
- Four of six patients achieved durable platelet responses; two had platelet levels ≥100x10^3/µL for over 24 weeks.
- Of four patients previously treated with rituximab, three responded to budoprutug, two with durable/complete responses.

## SEC filing metadata
- accession: 0001193125-26-266688
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2026-06-11T11:12:53+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312526266688/0001193125-26-266688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312526266688/d63753d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-266688
- JSON: https://secwatch.observer/filing/0001193125-26-266688.json
- Plain text: https://secwatch.observer/filing/0001193125-26-266688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.